#United States #Los Angeles #Lung Cancer #Actinium #ATNM-400

Actinium Pharmaceuticals Showcases New ATNM-400 Data at SNMMI 2026

On June 2, 2026, Actinium Pharmaceuticals, Inc. unveiled promising new preclinical data concerning ATNM-400, a novel radio-conjugate therapy, targeting KRAS and EGFR mutations in non-small cell lung cancer (NSCLC) at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting held in Los Angeles, California. This research highlights the innovative potential of ATNM-400 as a mutation-agnostic therapeutic option, potentially transforming treatment paradigms for a significant subset of lung cancer patients.

Key Findings and Implications

The newly presented data indicates that ATNM-400 displays superior efficacy when compared to the standard-of-care inhibitors, sotorasib and adagrasib, particularly in KRAS-mutant models. This therapy demonstrated a remarkable ability to enhance the expression of its target molecules up to 3.5- and 3.8-fold respectively when combined with these inhibitors. This synergy hints at ATNM-400's capability to drastically improve tumor cell death beyond what each standard therapy can achieve on its own.

Notably, in models exhibiting EGFR mutations, a powerful combination with osimertinib resulted in complete tumor regression and 107% tumor growth inhibition, showcasing the potential for ATNM-400 to serve as a foundational therapy that addresses multiple mutations concurrently.

This promising activity across two major mutation classes in NSCLC, accounting for 40-50% of all cases, suggests that ATNM-400 can be strategically positioned as a backbone therapy that is not limited to specific mutation targets but can also be effectively combined with existing treatments. NSCLC represents a substantial market, with over two million diagnoses globally each year and no single mutation dominating, making this breakthrough particularly significant.

The Science Behind ATNM-400

ATNM-400 utilizes Actinium-225, delivering high-linear-energy-transfer alpha particles that induce irreversible double-strand DNA breaks within tumor cells, independent of the mutation type affecting them. This presents a unique approach compared to conventional therapies, which typically focus on specific mutations like EGFR or BRAF.

Presenting equivalently strong evidence, preclinical models demonstrated that ATNM-400 successfully targeted approximately 98% of NSCLC tumors, signifying its broad application potential. In essence, it provides a pathway for treatment in a space that is often divided by rapid resistance and mutation specificity. This universal targeting establishes a more durable treatment solution from Actinium Pharmaceuticals.

Market Potential and Next Steps

The potential market for KRAS and EGFR inhibitors suggests lucrative opportunities, with projections exceeding $20 billion, indicating ATNM-400 may tap into established sectors while simultaneously reaching a broader patient demographic. By targeting tumors with high expression of the antigen while remaining effective against resistant variants, ATNM-400 stands to advance the treatment landscape of NSCLC significantly.

Professional Insights

Sandesh Seth, Chairman and CEO of Actinium, articulated the potential ofATNM-400, stating, "Our findings reinforce our belief that ATNM-400 exemplifies a fundamentally new approach in treating solid tumors in NSCLC. In contrast to most therapies targeting singular mutations, ATNM-400 showcases powerful, mutation-independent cell-killing capabilities, making it applicable across various patient populations."

With further development and clinical translation, ATNM-400 not only stands as a beacon of hope for NSCLC treatment but may also extend its influence into multiple solid tumor indications. As Actinium focuses on advancing this pipeline, their commitment to innovative oncology solutions remains steadfast, marking a significant moment in the battle against cancer.